Glioblastoma multiforme (GBM) is the most aggressive type of primary brain tumor and is
associated with a poor clinical prognosis. Despite the progress in the understanding of the …

Simple Summary Only 5% of all drug-related targets currently move from preclinical to
clinical in cancer, and just some of them achieve patient's bedside. Among others, intratumor …

Malignant glioma constitutes one of the fatal primary brain tumors in adults. Such poor
prognosis calls for a better understanding of cancer-related signaling pathways of this …

Natural compounds with pharmacological activity, flavonoids have been the subject of an
exponential increase in studies in the field of scientific research focused on therapeutic …

In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the
therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics …

Advancements in both material science and bionanotechnology are transforming the health
care sector. To this end, nanoparticles are increasingly used to improve diagnosis …

In the treatment of brain diseases, most potent drugs that have been developed exhibit poor
therapeutic outcomes resulting from the inability of a therapeutic amount of the drug to reach …

Numerous nanoparticles drug delivery systems for therapeutic implications in cancer
treatment are in preclinical development as conventional chemotherapy has several …

Background Glioma has a poor prognosis, and is the most common primary and lethal
primary malignant tumor in the central nervous system. Retinoic acid receptor-related …

Rapid vascular growth, infiltrative cells and high tumor heterogenicity are some glioblastoma
multiforme (GBM) characteristics, making it the most lethal form of brain cancer. Low efficacy …